One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Daniel J. Drucker
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight, fostering investigation of GLP1RA for the treatment of obesity. SCOPE OF REVIEW: Here I discuss the physiology of Glucagon-like peptide-1 (GLP-1) action in the control of food intake in animals and humans, highlighting the importance of gut vs. brain-derived GLP-1 for the control of feeding and body weight. The widespread distribution and function of multiple GLP-1 receptor (GLP1R) populations in the central and autonomic nervous system are outlined, and the importance of pathways controlling energy expenditure in preclinical studies vs. reduction of food intake in both animals and humans is highlighted. The relative contributions of vagal afferent pathways vs. GLP1R+ populations in the central nervous system for the physiological reduction of food intake and the anorectic response to GLP1RA are compared and reviewed. Key data enabling the development of two GLP1RA for obesity therapy (liraglutide 3 mg daily and semaglutide 2.4 mg once weekly) are discussed. Finally, emerging data potentially supporting the combination of GLP-1 with additional peptide epitopes in unimolecular multi-agonists, as well as in fixed-dose combination therapies, are highlighted. MAJOR CONCLUSIONS: The actions of GLP-1 to reduce food intake and body weight are highly conserved in obese animals and humans, in both adolescents and adults. The well-defined mechanisms of GLP-1 action through a single G protein-coupled receptor, together with the extensive safety database of GLP1RA in people with T2D, provide reassurance surrounding the long-term use of these agents in people with obesity and multiple co-morbidities. GLP1RA may also be effective in conditions associated with obesity, such as cardiovascular disease and non-alcoholic steatohepatitis (NASH). Progressive improvements in the efficacy of GLP1RA suggest that GLP-1-based therapies may soon rival bariatric surgery as viable options for the treatment of obesity and its complications.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Drucker, D. J. (2021). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. https://doi.org/10.1016/j.molmet.2021.101351
Drucker, Daniel J. "GLP-1 physiology informs the pharmacotherapy of obesity." Molecular Metabolism, vol. 57, 2021, pp. 101351, https://doi.org/10.1016/j.molmet.2021.101351.
Drucker, Daniel J. "GLP-1 physiology informs the pharmacotherapy of obesity." Molecular Metabolism 57 (2021): 101351. https://doi.org/10.1016/j.molmet.2021.101351.
Drucker D. J. GLP-1 physiology informs the pharmacotherapy of obesity // Molecular Metabolism. — 2021. — Vol. 57. — P. 101351. — URL: https://doi.org/10.1016/j.molmet.2021.101351
@article{drucker2021physiology,
title = {{GLP-1 physiology informs the pharmacotherapy of obesity}},
author = {Daniel J. Drucker},
journal = {Molecular Metabolism},
year = {2021},
volume = {57},
pages = {101351},
doi = {10.1016/j.molmet.2021.101351},
url = {https://doi.org/10.1016/j.molmet.2021.101351}
}TY - JOUR AU - Drucker, Daniel J. TI - GLP-1 physiology informs the pharmacotherapy of obesity JO - Molecular Metabolism VL - 57 SP - 101351 PY - 2021 DA - 2021/10/08 DO - 10.1016/j.molmet.2021.101351 UR - https://doi.org/10.1016/j.molmet.2021.101351 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.